Partnerships
At Exosome Diagnostics, collaboration is a key focus of both our business and our culture. We are establishing partnerships with industry, academia, advocacy, and governmental organizations to help advance the application and potential of our exosome-based technology.
Find out more about our collaborations with:
- Academic institutions, advocacy groups, and government to develop diagnostics
- Biopharma industry to discover new biomarkers and develop companion diagnostics
The Most Comprehensive Biofluid-Based Molecular Analysis Platform
A variety of companies and organizations choose to work with Exosome Diagnostics because our platform enables:
- Efficient isolation of RNA from exosomes
- Molecular testing across a range of disease areas
- Biomarker discovery and the development of companion diagnostics
For maximum mutation detection, we offer the only single-capture exosomal RNA and cell-free DNA (cfDNA) combined extraction from the same sample, allowing for the greatest total yield of nucleic acids for rare mutation detection. This presents a distinct advantage, as solely utilizing a cfDNA platform cannot enable the capture or analysis of critical exosomal RNA.
| Top-Line Comparison | Exosomes | cfDNA | CTC |
|---|---|---|---|
| Analysis Capability | |||
| Combines the mutation analysis power of RNA, DNA and cfDNA for increased sensitivity | Yes | No | No |
| Analysis of RNA transcription profiles (mRNA, splice variants, miRNA, IncRNA, etc.) | Yes | No | Yes* |
| Detects systemic changes to disease | Yes | No | No |
| Analysis of RNA/DNA/protein profiles from tumor cells that are still alive inside the solid tumor | Yes | No** | No*** |
| Protein status | Yes | No | Yes |
| Clinical Utility | |||
| Real-time snapshot of events in the tumor | Yes | Yes | Yes |
| Simple workflow of sample acquisition and processing | Yes | Yes | No |
| Fresh or frozen biobanked material | Yes | Yes | No |
| Broad applicability beyond oncology | Yes | No | No |
* Only some CTC platforms
** cfDNA is only released from dying cells
*** Most CTCs will never metastisize, unclear how the transcriptome status compares to cells within the tumor
cfDNA: Cell-Free or Circulating-Free Diagnostics
CTCs: Circulating Tumor Cells
